Date: Thursday 10th December 2020 Time: 15:00 - 16:00 GMT Speaker: Scott Patterson (Sanofi)
Who is this event intended for? Statisticians interested in the statistics of crisis vaccine clinical studies, like those being done for COVID-19.
What is the benefit of attending? Those attending will learn of several statistical observations on crisis vaccine clinical development that are important to an understanding of data generated in COVID-19 vaccine development and other crisis clinical vaccine programs.
Registration
You can now register for this event. Registration will close at 12:00 on 9th December 2020.
This event is free of charge to both Members and Non Members of PSI.
To register your place, please click here.
Overview
Scott Patterson, Bo Fu, Ya Meng, Fabrice Bailleux, Josh Chen.
Statistical Observations on SARS-CoV-2 & Crisis Vaccine Clinical Testing.
Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is following this traditional development pathway, but accelerated Phase I-II-III clinical programs are being applied (c.f., USA FDA guidances 2020). This is not the first time vaccines have been manufactured and tested quickly to meet a public health crisis (1976, 2009). Selected statistical concepts pertaining to vaccine efficacy and safety, relevant during the design and implementation of such crisis programs, will be discussed.
Speaker Details
Speaker
Biography
Scott Patterson (Sanofi)
Scott Patterson PhD, PStat is currently the head of Statistical Innovation at Sanofi Pasteur, the vaccines’ division of Sanofi. He and co-author Professor Byron Jones wrote `Bioequivalence and Statistics in Clinical Pharmacology’ now in its second edition. Scott has over 25 years of professional experience in biostatistics, and he and his family reside in Pennsylvania, USA.
Scientific Meetings
PSI Vaccine SIG Webinar: Some considerations on developing COVID-19 Vaccines
Date: Thursday 10th December 2020 Time: 15:00 - 16:00 GMT Speaker: Scott Patterson (Sanofi)
Who is this event intended for? Statisticians interested in the statistics of crisis vaccine clinical studies, like those being done for COVID-19.
What is the benefit of attending? Those attending will learn of several statistical observations on crisis vaccine clinical development that are important to an understanding of data generated in COVID-19 vaccine development and other crisis clinical vaccine programs.
Registration
You can now register for this event. Registration will close at 12:00 on 9th December 2020.
This event is free of charge to both Members and Non Members of PSI.
To register your place, please click here.
Overview
Scott Patterson, Bo Fu, Ya Meng, Fabrice Bailleux, Josh Chen.
Statistical Observations on SARS-CoV-2 & Crisis Vaccine Clinical Testing.
Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is following this traditional development pathway, but accelerated Phase I-II-III clinical programs are being applied (c.f., USA FDA guidances 2020). This is not the first time vaccines have been manufactured and tested quickly to meet a public health crisis (1976, 2009). Selected statistical concepts pertaining to vaccine efficacy and safety, relevant during the design and implementation of such crisis programs, will be discussed.
Speaker Details
Speaker
Biography
Scott Patterson (Sanofi)
Scott Patterson PhD, PStat is currently the head of Statistical Innovation at Sanofi Pasteur, the vaccines’ division of Sanofi. He and co-author Professor Byron Jones wrote `Bioequivalence and Statistics in Clinical Pharmacology’ now in its second edition. Scott has over 25 years of professional experience in biostatistics, and he and his family reside in Pennsylvania, USA.
Training Courses
PSI Vaccine SIG Webinar: Some considerations on developing COVID-19 Vaccines
Date: Thursday 10th December 2020 Time: 15:00 - 16:00 GMT Speaker: Scott Patterson (Sanofi)
Who is this event intended for? Statisticians interested in the statistics of crisis vaccine clinical studies, like those being done for COVID-19.
What is the benefit of attending? Those attending will learn of several statistical observations on crisis vaccine clinical development that are important to an understanding of data generated in COVID-19 vaccine development and other crisis clinical vaccine programs.
Registration
You can now register for this event. Registration will close at 12:00 on 9th December 2020.
This event is free of charge to both Members and Non Members of PSI.
To register your place, please click here.
Overview
Scott Patterson, Bo Fu, Ya Meng, Fabrice Bailleux, Josh Chen.
Statistical Observations on SARS-CoV-2 & Crisis Vaccine Clinical Testing.
Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is following this traditional development pathway, but accelerated Phase I-II-III clinical programs are being applied (c.f., USA FDA guidances 2020). This is not the first time vaccines have been manufactured and tested quickly to meet a public health crisis (1976, 2009). Selected statistical concepts pertaining to vaccine efficacy and safety, relevant during the design and implementation of such crisis programs, will be discussed.
Speaker Details
Speaker
Biography
Scott Patterson (Sanofi)
Scott Patterson PhD, PStat is currently the head of Statistical Innovation at Sanofi Pasteur, the vaccines’ division of Sanofi. He and co-author Professor Byron Jones wrote `Bioequivalence and Statistics in Clinical Pharmacology’ now in its second edition. Scott has over 25 years of professional experience in biostatistics, and he and his family reside in Pennsylvania, USA.
Journal Club
PSI Vaccine SIG Webinar: Some considerations on developing COVID-19 Vaccines
Date: Thursday 10th December 2020 Time: 15:00 - 16:00 GMT Speaker: Scott Patterson (Sanofi)
Who is this event intended for? Statisticians interested in the statistics of crisis vaccine clinical studies, like those being done for COVID-19.
What is the benefit of attending? Those attending will learn of several statistical observations on crisis vaccine clinical development that are important to an understanding of data generated in COVID-19 vaccine development and other crisis clinical vaccine programs.
Registration
You can now register for this event. Registration will close at 12:00 on 9th December 2020.
This event is free of charge to both Members and Non Members of PSI.
To register your place, please click here.
Overview
Scott Patterson, Bo Fu, Ya Meng, Fabrice Bailleux, Josh Chen.
Statistical Observations on SARS-CoV-2 & Crisis Vaccine Clinical Testing.
Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is following this traditional development pathway, but accelerated Phase I-II-III clinical programs are being applied (c.f., USA FDA guidances 2020). This is not the first time vaccines have been manufactured and tested quickly to meet a public health crisis (1976, 2009). Selected statistical concepts pertaining to vaccine efficacy and safety, relevant during the design and implementation of such crisis programs, will be discussed.
Speaker Details
Speaker
Biography
Scott Patterson (Sanofi)
Scott Patterson PhD, PStat is currently the head of Statistical Innovation at Sanofi Pasteur, the vaccines’ division of Sanofi. He and co-author Professor Byron Jones wrote `Bioequivalence and Statistics in Clinical Pharmacology’ now in its second edition. Scott has over 25 years of professional experience in biostatistics, and he and his family reside in Pennsylvania, USA.
Webinars
PSI Vaccine SIG Webinar: Some considerations on developing COVID-19 Vaccines
Date: Thursday 10th December 2020 Time: 15:00 - 16:00 GMT Speaker: Scott Patterson (Sanofi)
Who is this event intended for? Statisticians interested in the statistics of crisis vaccine clinical studies, like those being done for COVID-19.
What is the benefit of attending? Those attending will learn of several statistical observations on crisis vaccine clinical development that are important to an understanding of data generated in COVID-19 vaccine development and other crisis clinical vaccine programs.
Registration
You can now register for this event. Registration will close at 12:00 on 9th December 2020.
This event is free of charge to both Members and Non Members of PSI.
To register your place, please click here.
Overview
Scott Patterson, Bo Fu, Ya Meng, Fabrice Bailleux, Josh Chen.
Statistical Observations on SARS-CoV-2 & Crisis Vaccine Clinical Testing.
Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is following this traditional development pathway, but accelerated Phase I-II-III clinical programs are being applied (c.f., USA FDA guidances 2020). This is not the first time vaccines have been manufactured and tested quickly to meet a public health crisis (1976, 2009). Selected statistical concepts pertaining to vaccine efficacy and safety, relevant during the design and implementation of such crisis programs, will be discussed.
Speaker Details
Speaker
Biography
Scott Patterson (Sanofi)
Scott Patterson PhD, PStat is currently the head of Statistical Innovation at Sanofi Pasteur, the vaccines’ division of Sanofi. He and co-author Professor Byron Jones wrote `Bioequivalence and Statistics in Clinical Pharmacology’ now in its second edition. Scott has over 25 years of professional experience in biostatistics, and he and his family reside in Pennsylvania, USA.
Careers Meetings
PSI Vaccine SIG Webinar: Some considerations on developing COVID-19 Vaccines
Date: Thursday 10th December 2020 Time: 15:00 - 16:00 GMT Speaker: Scott Patterson (Sanofi)
Who is this event intended for? Statisticians interested in the statistics of crisis vaccine clinical studies, like those being done for COVID-19.
What is the benefit of attending? Those attending will learn of several statistical observations on crisis vaccine clinical development that are important to an understanding of data generated in COVID-19 vaccine development and other crisis clinical vaccine programs.
Registration
You can now register for this event. Registration will close at 12:00 on 9th December 2020.
This event is free of charge to both Members and Non Members of PSI.
To register your place, please click here.
Overview
Scott Patterson, Bo Fu, Ya Meng, Fabrice Bailleux, Josh Chen.
Statistical Observations on SARS-CoV-2 & Crisis Vaccine Clinical Testing.
Traditional vaccine clinical development is an undertaking involving meticulous, multiple studies in multiple populations at risk of infection and disease over multiple years. SARS-CoV-2 and COVID-19 vaccine development is following this traditional development pathway, but accelerated Phase I-II-III clinical programs are being applied (c.f., USA FDA guidances 2020). This is not the first time vaccines have been manufactured and tested quickly to meet a public health crisis (1976, 2009). Selected statistical concepts pertaining to vaccine efficacy and safety, relevant during the design and implementation of such crisis programs, will be discussed.
Speaker Details
Speaker
Biography
Scott Patterson (Sanofi)
Scott Patterson PhD, PStat is currently the head of Statistical Innovation at Sanofi Pasteur, the vaccines’ division of Sanofi. He and co-author Professor Byron Jones wrote `Bioequivalence and Statistics in Clinical Pharmacology’ now in its second edition. Scott has over 25 years of professional experience in biostatistics, and he and his family reside in Pennsylvania, USA.
Upcoming Events
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
PSI Training Course: Regulatory Guidelines for Statisticians
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
In this event, we’ll start with a general introduction to hierarchical composite endpoints and an overview of common analysis methods including win ratio, win odds, and net benefit. Then, the practical considerations will be illustrated through case studies from clinical trials in heart failure and chronic kidney disease. We conclude with a discussion and a Q&A.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
Senior Medical Statistician & Statistical Programmer
An exciting opportunity has arisen for a Senior Medical Statistician & Statistical Programmer to join the UKCRC fully registered Derby Clinical Trials Support Unit (Derby CTSU).
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK